ProCE Banner Activity

monarchE: Molecular Profiling of Primary Tumor Tissue and ctDNA Detection in Patients With High-Risk, Node-Positive HR+/HER2- EBC Treated With Adjuvant ET ± Abemaciclib

Conference Coverage

Analysis of monarchE showed the addition of abemaciclib to adjuvant ET improved invasive disease–free survival in patients with node-positive, high-risk HR-positive/HER2-negative early breast cancer irrespective of molecular subtype, inferred Oncotype-RNA risk score, and across most common genomic alterations while a pilot study found that ctDNA positivity at baseline and 24 months is predictive of recurrence in monarchE participants.

Released: December 10, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.